Novartis transformation into a pure-play Innovative Medicines company @Novartis
Novartis transformation into a pure-play Innovative Medicines company  @Novartis
Uploaded January 2023 | Updated November 2026, 3 days ago
Novartis’s transformation into a pure-play Innovative Medicines company was outlined to investors by our CEO, Vas Narasimhan.

Our refreshed vision is to become the most valued and trusted medicines company in the world.

Our strategy is to deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches.

This new strategy provides a focus on core therapeutic areas (Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology), technology platforms, and priority geographies.

0:00 Evolution to pure-play
0:31 Vision
0:49 Strategy
2:14 R&D focus
3:36 Summary - top takeaways

JP Morgan Healthcare Conference
Event Date: January 9, 2023
Investors Events: bit.ly/3D1yxr5
Novartis Strategy: bit.ly/3klog2m

Disclaimer: JP Morgan healthcare conference event contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: bit.ly/3kwTJyU

Follow @Novartis on Twitter: twitter.com/Novartis
Follow Novartis on LinkedIn: linkedin.com/company/novartis
Novartis transformation into a pure-play Innovative Medicines companyHow does Novartis create value for stakeholders and society?The latest in cancer care: Why Ankur is excitedRedefining CML care at NovartisWhat does belonging mean to you? Lalit’s storyPast Present & Future of CAR-TTaking out cancer’s trashCelebrating International Volunteer Day 2022 - #ThankYouVolunteersRaise Your Voice: Speaking Up About Living With Lung CancerWellbeing starts with me, you, usHow mini is a mini-heart?Novartis Strategic Business Deals in 2023
Novartis |

Novartis transformation into a pure-play Innovative Medicines company

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER